Further implementation of evidence‐based medications, with maximal tolerated or target dose,29 including the angiotensin receptor neprilysin inhibitor and sodium‐glucose cotransporter 2 (SGLT2) inhibitors would be required to reduce heart failure death in CRT‐D patients. This evidence concerns the gene SLC5A2 and heart failure.